Barclays Maintains Overweight on Revance Therapeutics, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowered the price target from $40 to $35.
October 23, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics' price target has been lowered by Barclays from $40 to $35, though the Overweight rating is maintained.
The lowering of the price target by Barclays indicates a potential decrease in the short-term value of Revance Therapeutics' stock. However, the maintained Overweight rating suggests that the stock is still expected to outperform.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100